Using pharmacological chaperones to restore proteostasis

Pharmacological Research

Volumn 83, Issue , 2014, Pages 3-9

  Wang, Ya Juan ^a   Di, Xiao Jing ^a   Mu, Ting Wei ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chaperone; ERAD; GPCR; Ion channel; Lysosomal storage disease; Pharmacological chaperone; Protein misfolding disease; Proteostasis

Indexed keywords

CHAPERONE;

INTRACELLULAR SPACE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN HOMEOSTASIS; PROTEIN SYNTHESIS; PROTEIN TRANSPORT; REVIEW;

EID: 84901840776     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2014.04.002     Document Type: Review

References (97)

1. W.E. Balch, R.I. Morimoto, A. Dillin, and J.W. Kelly Adapting proteostasis for disease intervention Science 319 2008 916 919 (Pubitemid 351263754)
2. Y.E. Kim, M.S. Hipp, A. Bracher, M. Hayer-Hartl, and F.U. Hartl Molecular chaperone functions in protein folding and proteostasis Annu Rev Biochem 82 2013 323 355
3. C.J. Guerriero, and J.L. Brodsky The delicate balance between secreted protein folding and endoplasmic reticulum-associated degradation in human physiology Physiol Rev 92 2012 537 576
4. E.T. Powers, and W.E. Balch Diversity in the origins of proteostasis networks - a driver for protein function in evolution Nat Rev Mol Cell Biol 14 2013 237 248
5. T. Gidalevitz, V. Prahlad, and R.I. Morimoto The stress of protein misfolding: from single cells to multicellular organisms Cold Spring Harb Perspect Biol 3 2011 a009704
6. J. Labbadia, and R.I. Morimoto Proteostasis and longevity: when does aging really begin? F1000prime Rep 6 2014 7
7. D. Vilchez, M.S. Simic, and A. Dillin Proteostasis and aging of stem cells Trends Cell Biol 24 2014 161 170
8. W.E. Balch, D.M. Roth, and D.M. Hutt Emergent properties of proteostasis in managing cystic fibrosis Cold Spring Harb Perspect Biol 3 2011 a004499
9. G.L. Lukacs, and A.S. Verkman CFTR: folding, misfolding and correcting the DeltaF508 conformational defect Trends Mol Med 18 2012 81 91
10. B.P. Delisle, B.D. Anson, S. Rajamani, and C.T. January Biology of cardiac arrhythmias - ion channel protein trafficking Circ Res 94 2004 1418 1428 (Pubitemid 38780314)
11. O.K. Steinlein Ion channel mutations in neuronal diseases: a genetics perspective Chem Rev 112 2012 6334 6352
12. V. Bernier, D.G. Bichet, and M. Bouvier Pharmacological chaperone action on G-protein-coupled receptors Curr Opin Pharmacol 4 2004 528 533 (Pubitemid 40533016)
13. P.M. Conn, A. Ulloa-Aguirre, J. Ito, and J.A. Janovick G protein-coupled receptor trafficking in health and disease: lessons learned to prepare for therapeutic mutant rescue in vivo Pharmacol Rev 59 2007 225 250 (Pubitemid 47481435)
14. G.A. Grabowski Gaucher disease and other storage disorders Hematol Am Soc Hematol Educ Program 2012 2012 13 18
15. P. Arosio, M. Vendruscolo, C.M. Dobson, and T.P. Knowles Chemical kinetics for drug discovery to combat protein aggregation diseases Trends Pharmacol Sci 35 2014 127 135
16. E.T. Powers, R.I. Morimoto, A. Dillin, J.W. Kelly, and W.E. Balch Biological and chemical approaches to diseases of proteostasis deficiency Annu Rev Biochem 78 2009 959 991
17. S.L. Lindquist, and J.W. Kelly Chemical and biological approaches for adapting proteostasis to ameliorate protein misfolding and aggregation diseases: progress and prognosis Cold Spring Harb Perspect Biol 3 2011 a004507
18. T.W. Mu, D.S.T. Ong, Y.J. Wang, W.E. Balch, J.R. Yates, and L. Segatori et al. Chemical and biological approaches synergize to ameliorate protein-folding diseases Cell 134 2008 769 781
19. X.-J. Di, D.-Y. Han, Y.-J. Wang, M.R. Chance, and T.-W. Mu SAHA enhances proteostasis of epilepsy-associated alpha1(A322D)beta2gamma2 GABAA receptors Chem Biol 20 2013 1456 1468
20. S. Lindquist The heat-shock response Annu Rev Biochem 55 1986 1151 1191 (Pubitemid 16070798)
21. M. Schroder, and R.J. Kaufman The mammalian unfolded protein response Annu Rev Biochem 74 2005 739 789 (Pubitemid 40995523)
22. P. Walter, and D. Ron The unfolded protein response: from stress pathway to homeostatic regulation Science 334 2011 1081 1086
23. T.W. Mu, D.M. Fowler, and J.W. Kelly Partial restoration of mutant enzyme homeostasis in three distinct lysosomal storage disease cell lines by altering calcium homeostasis PLoS Biol 6 2008 e26
24. 2+ increases enhance mutant glucocerebrosidase proteostasis Nat Chem Biol 6 2010 424 432
25. J.L. Brodsky Cleaning up: ER-associated degradation to the rescue Cell 151 2012 1163 1167
26. D.J. Klionsky, and S.D. Emr Cell biology - autophagy as a regulated pathway of cellular degradation Science 290 2000 1717 1721 (Pubitemid 32004796)
27. D.S. Ong, Y.J. Wang, Y.L. Tan, J.R. Yates 3rd, T.W. Mu, and J.W. Kelly FKBP10 depletion enhances glucocerebrosidase proteostasis in Gaucher disease fibroblasts Chem Biol 20 2013 403 415
28. X.D. Wang, J. Venable, P. LaPointe, D.M. Hutt, A.V. Koulov, and J. Coppinger et al. Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis Cell 127 2006 803 815 (Pubitemid 44716255)
29. Y.J. Wang, D.Y. Han, T. Tabib, J.R. Yates, and T.W. Mu Identification of GABAC receptor protein homeostasis network components from three tandem mass spectrometry proteomics approaches J Proteome Res 27 2013 5570 5586
30. Y. Zhang, B.R. Fonslow, B. Shan, M.C. Baek, and J.R. Yates 3rd. Protein analysis by shotgun/bottom-up proteomics Chem Rev 113 2013 2343 2394
31. D.N. Hebert, and M. Molinari Flagging and docking: dual roles for N-glycans in protein quality control and cellular proteostasis Trends Biochem Sci 37 2012 404 410
32. E. Mohorko, R. Glockshuber, and M. Aebi Oligosaccharyltransferase: the central enzyme of N-linked protein glycosylation J Inherit Metab Dis 34 2011 869 878
33. M. Aebi N-linked protein glycosylation in the ER Trends Cell Biol 1833 2013 2430 2437
34. S.P. Ferris, V.K. Kodali, and R.J. Kaufman Glycoprotein folding and quality-control mechanisms in protein-folding diseases Dis Model Mech 7 2014 331 341
35. G.Z. Lederkremer Glycoprotein folding, quality control and ER-associated degradation Curr Opin Struct Biol 19 2009 515 523
36. E. van Anken, and I. Braakman Versatility of the endoplasmic reticulum protein folding factory Crit Rev Biochem Mol Biol 40 2005 191 228 (Pubitemid 41140882)
37. B. Bukau, and A.L. Horwich The Hsp70 and Hsp60 chaperone machines Cell 92 1998 351 366 (Pubitemid 28093013)
38. F.U. Hartl Molecular chaperones in cellular protein folding Nature 381 1996 571 580 (Pubitemid 26177472)
39. I. Braakman, and D.N. Hebert Protein folding in the endoplasmic reticulum Cold Spring Harb Perspect Biol 5 2013 a013201
40. B. Bukau, J. Weissman, and A. Horwich Molecular chaperones and protein quality control Cell 125 2006 443 451
41. F.U. Hartl, A. Bracher, and M. Hayer-Hartl Molecular chaperones in protein folding and proteostasis Nature 475 2011 324 332
42. K.E. Routledge, V. Gupta, and W.E. Balch Emergent properties of proteostasis-COPII coupled systems in human health and disease Mol Membr Biol 27 2010 385 397
43. G. Zanetti, K.B. Pahuja, S. Studer, S. Shim, and R. Schekman COPII and the regulation of protein sorting in mammals Nat Cell Biol 14 2012 20 28
44. T. Szul, and E. Sztul COPII and COPI traffic at the ER-Golgi interface Physiology 26 2011 348 364
45. R.E. Boyd, G. Lee, P. Rybczynski, E.R. Benjamin, R. Khanna, and B.A. Wustman et al. Pharmacological chaperones as therapeutics for lysosomal storage diseases J Med Chem 56 2013 2705 2725
46. G. Maya-Nunez, A. Ulloa-Aguirre, J.A. Janovick, and P.M. Conn Pharmacological chaperones correct misfolded GPCRs and rescue function: protein trafficking as a therapeutic target Subcell Biochem 63 2012 263 289
47. R. Srinivasan, C.I. Richards, C. Xiao, D. Rhee, R. Pantoja, and D.A. Dougherty et al. Pharmacological chaperoning of nicotinic acetylcholine receptors reduces the endoplasmic reticulum stress response Mol Pharmacol 81 2012 759 769
48. T.W. Loo, M.C. Bartlett, and D.M. Clarke Rescue of folding defects in ABC transporters using pharmacological chaperones J Bioenerg Biomembr 37 2005 501 507 (Pubitemid 43725183)
49. S.M. Johnson, S. Connelly, C. Fearns, E.T. Powers, and J.W. Kelly The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug J Mol Biol 421 2012 185 203
50. C.E. Prada, and G.A. Grabowski Neuronopathic lysosomal storage diseases: clinical and pathologic findings Dev Disabil Res Rev 17 2013 226 246
51. A.D. Klein, and A.H. Futerman Lysosomal storage disorders: old diseases, present and future challenges Pediatr Endocrinol Rev 11 Suppl. 1 2013 59 63
52. I. Bendikov-Bar, and M. Horowitz Gaucher disease paradigm: from ERAD to comorbidity Hum Mutat 33 2012 1398 1407
53. R. Giugliani, S. Waldek, D.P. Germain, K. Nicholls, D.G. Bichet, and J.K. Simosky et al. A phase 2 study of migalastat hydrochloride in females with Fabry disease: selection of population, safety and pharmacodynamic effects Mol Genet Metab 109 2013 86 92
54. S. Ishii Pharmacological chaperone therapy for Fabry disease Proc Jpn Acad Ser B Phys Biol Sci 88 2012 18 30
55. B.E. Rosenbloom, and N.J. Weinreb Gaucher disease: a comprehensive review Crit Rev Oncog 18 2013 163 175
56. J.Q. Fan, S. Ishii, N. Asano, and Y. Suzuki Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor Nat Med 5 1999 112 115 (Pubitemid 29051008)
57. J.Q. Fan A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity Trends Pharmacol Sci 24 2003 355 360
58. Z. Yu, A.R. Sawkar, and J.W. Kelly Pharmacologic chaperoning as a strategy to treat Gaucher disease FEBS J 274 2007 4944 4950 (Pubitemid 47481193)
59. K.J. Valenzano, R. Khanna, A.C. Powe, R. Boyd, G. Lee, and J.J. Flanagan et al. Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders Assay Drug Dev Technol 9 2011 213 235
60. A. Kato, Y. Yamashita, S. Nakagawa, Y. Koike, I. Adachi, and J. Hollinshead et al. 2,5-Dideoxy-2,5-imino-d-altritol as a new class of pharmacological chaperone for Fabry disease Bioorg Med Chem 18 2010 3790 3794
61. G. Andreotti, V. Citro, A. Correra, and M.V. Cubellis A thermodynamic assay to test pharmacological chaperones for Fabry disease Biochim Biophys Acta 1840 2014 1214 1224
62. A.I. Guce, N.E. Clark, J.J. Rogich, and S.C. Garman The molecular basis of pharmacological chaperoning in human alpha-galactosidase Chem Biol 18 2011 1521 1526
63. A.R. Sawkar, W.C. Cheng, E. Beutler, C.H. Wong, W.E. Balch, and J.W. Kelly Chemical chaperones increase the cellular activity of N370S beta-glucosidase: a therapeutic strategy for Gaucher disease Proc Natl Acad Sci USA 99 2002 15428 15433 (Pubitemid 35403951)
64. A.R. Sawkar, M. Schmitz, K.P. Zimmer, D. Reczek, T. Edmunds, and W.E. Balch et al. Chemical chaperones and permissive temperatures alter localization of Gaucher disease associated glucocerebrosidase variants ACS Chem Biol 1 2006 235 251
65. L. Diaz, J. Bujons, J. Casas, A. Llebaria, and A. Delgado Click chemistry approach to new N-substituted aminocyclitols as potential pharmacological chaperones for Gaucher disease J Med Chem 53 2010 5248 5255
66. A. Trapero, and A. Llebaria Glucocerebrosidase inhibitors for the treatment of Gaucher disease Future Med Chem 5 2013 573 590
67. Z. Yu, A.R. Sawkar, L.J. Whalen, C.-H. Wong, and J.W. Kelly Isofagomine- and 2,5-anhydro-2,5-imino-d-glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention J Med Chem 50 2007 94 100 (Pubitemid 46105502)
68. F.M. Ashcroft Ion channels and disease: channelopathies 2000 Academic Press San Diego, CA
69. Z. Zhou, Q. Gong, and C.T. January Correction of defective protein trafficking of a mutant HERG potassium channel in human long QT syndrome. Pharmacological and temperature effects J Biol Chem 274 1999 31123 31126
70. J.W. Hanrahan, H.M. Sampson, and D.Y. Thomas Novel pharmacological strategies to treat cystic fibrosis Trends Pharmacol Sci 34 2013 119 125
71. R.S. Eshaq, L.D. Stahl, R. Stone 2nd, S.S. Smith, L.C. Robinson, and N.J. Leidenheimer GABA acts as a ligand chaperone in the early secretory pathway to promote cell surface expression of GABAA receptors Brain Res 1346 2010 1 13
72. A. Kuryatov, J. Luo, J. Cooper, and J. Lindstrom Nicotine acts as a pharmacological chaperone to up-regulate human alpha 4 beta 2 acetylcholine receptors Mol Pharmacol 68 2005 1839 1851 (Pubitemid 41654365)
73. H.A. Lester, C. Xiao, R. Srinivasan, C.D. Son, J. Miwa, and R. Pantoja et al. Nicotine is a selective pharmacological chaperone of acetylcholine receptor number and stoichiometry. Implications for drug discovery AAPS J 11 2009 167 177
74. C.L. Anderson, B.P. Delisle, B.D. Anson, J.A. Kilby, M.L. Will, and D.J. Tester et al. Most LQT2 mutations reduce Kv11.1 (hERG) current by a class 2 (trafficking-deficient) mechanism Circulation 113 2006 365 373 (Pubitemid 43803197)
75. E. Ficker, C.A. Obejero-Paz, S. Zhao, and A.M. Brown The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-gogo-related gene (HERG) mutations J Biol Chem 277 2002 4989 4998 (Pubitemid 34968538)
76. Y. Wang, M.C. Bartlett, T.W. Loo, and D.M. Clarke Specific rescue of cystic fibrosis transmembrane conductance regulator processing mutants using pharmacological chaperones Mol Pharmacol 70 2006 297 302
77. Y. Wang, T.W. Loo, M.C. Bartlett, and D.M. Clarke Correctors promote maturation of cystic fibrosis transmembrane conductance regulator (CFTR)-processing mutants by binding to the protein J Biol Chem 282 2007 33247 33251 (Pubitemid 350159496)
78. H.M. Sampson, R. Robert, J. Liao, E. Matthes, G.W. Carlile, and J.W. Hanrahan et al. Identification of a NBD1-binding pharmacological chaperone that corrects the trafficking defect of F508del-CFTR Chem Biol 18 2011 231 242
79. L.J. Galietta, M.F. Springsteel, M. Eda, E.J. Niedzinski, K. By, and M.J. Haddadin et al. Novel CFTR chloride channel activators identified by screening of combinatorial libraries based on flavone and benzoquinolizinium lead compounds J Biol Chem 276 2001 19723 19728
80. C.J. Dacosta, and J.E. Baenziger Gating of pentameric ligand-gated ion channels: structural insights and ambiguities Structure 21 2013 1271 1283
81. H.A. Lester, M.I. Dibas, D.S. Dahan, J.F. Leite, and D.A. Dougherty Cys-loop receptors: new twists and turns Trends Neurosci 27 2004 329 336 (Pubitemid 38692414)
82. T.W. Mu, H.A. Lester, and D.A. Dougherty Different binding orientations for the same agonist at homologous receptors: a lock and key or a simple wedge? J Am Chem Soc 125 2003 6850 6851 (Pubitemid 36682767)
83. B.J. Henderson, R. Srinivasan, W.A. Nichols, C.N. Dilworth, D.F. Gutierrez, and E.D. Mackey et al. Nicotine exploits a COPI-mediated process for chaperone-mediated up-regulation of its receptors J Gen Physiol 143 2014 51 66
84. R. Srinivasan, R. Pantoja, F.J. Moss, E.D. Mackey, C.D. Son, and J. Miwa et al. Nicotine up-regulates alpha4beta2 nicotinic receptors and ER exit sites via stoichiometry-dependent chaperoning J Gen Physiol 137 2011 59 79
85. J.H. Dunham, and R.A. Hall Enhancement of the surface expression of G protein-coupled receptors Trends Biotechnol 27 2009 541 545
86. J.P. Morello, A. Salahpour, A. Laperriere, V. Bernier, M.F. Arthus, and M. Lonergan et al. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants J Clin Invest 105 2000 887 895 (Pubitemid 30203061)
87. V. Bernier, J.P. Morello, A. Zarruk, N. Debrand, A. Salahpour, and M. Lonergan et al. Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus J Am Soc Nephrol 17 2006 232 243
88. E.L. Los, P.M. Deen, and J.H. Robben Potential of nonpeptide (ant)agonists to rescue vasopressin V2 receptor mutants for the treatment of X-linked nephrogenic diabetes insipidus J Neuroendocrinol 22 2010 393 399
89. J.H. Robben, M. Sze, N.V. Knoers, and P.M. Deen Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus Am J Physiol Renal Physiol 292 2007 F253 F260
90. J.A. Janovick, G. Maya-Nunez, and P.M. Conn Rescue of hypogonadotropic hypogonadism-causing and manufactured GnRH receptor mutants by a specific protein-folding template: misrouted proteins as a novel disease etiology and therapeutic target J Clin Endocrinol Metab 87 2002 3255 3262 (Pubitemid 34816374)
91. J.A. Janovick, M.D. Stewart, D. Jacob, L.D. Martin, J.M. Deng, and C.A. Stewart et al. Restoration of testis function in hypogonadotropic hypogonadal mice harboring a misfolded GnRHR mutant by pharmacoperone drug therapy Proc Natl Acad Sci USA 110 2013 21030 21035
92. P.M. Conn, and A. Ulloa-Aguirre Pharmacological chaperones for misfolded gonadotropin-releasing hormone receptors Adv Pharmacol 62 2011 109 141
93. T.J. Hollingsworth, and A.K. Gross Defective trafficking of rhodopsin and its role in retinal degenerations Int Rev Cell Mol Biol 293 2012 1 44
94. S.M. Noorwez, V. Kuksa, Y. Imanishi, L. Zhu, S. Filipek, and K. Palczewski et al. Pharmacological chaperone-mediated in vivo folding and stabilization of the P23H-opsin mutant associated with autosomal dominant retinitis pigmentosa J Biol Chem 278 2003 14442 14450 (Pubitemid 36799997)
95. S.M. Noorwez, R. Malhotra, J.H. McDowell, K.A. Smith, M.P. Krebs, and S. Kaushal Retinoids assist the cellular folding of the autosomal dominant retinitis pigmentosa opsin mutant P23H J Biol Chem 279 2004 16278 16284 (Pubitemid 38509322)
96. M.P. Krebs, D.C. Holden, P. Joshi, C.L. Clark 3rd, A.H. Lee, and S. Kaushal Molecular mechanisms of rhodopsin retinitis pigmentosa and the efficacy of pharmacological rescue J Mol Biol 395 2010 1063 1078
97. U.E. Petaja-Repo, M. Hogue, S. Bhalla, A. Laperriere, J.P. Morello, and M. Bouvier Ligands act as pharmacological chaperones and increase the efficiency of delta opioid receptor maturation EMBO J 21 2002 1628 1637 (Pubitemid 34614619)